These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 18444791)

  • 21. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
    Nannini EC; Corey GR; Stryjewski ME
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.
    Lipsky BA; Stoutenburgh U
    J Antimicrob Chemother; 2005 Feb; 55(2):240-5. PubMed ID: 15659542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
    Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
    Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ
    Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
    Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
    Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
    Arbeit RD; Maki D; Tally FP; Campanaro E; Eisenstein BI;
    Clin Infect Dis; 2004 Jun; 38(12):1673-81. PubMed ID: 15227611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
    Rubinstein E; Cammarata S; Oliphant T; Wunderink R;
    Clin Infect Dis; 2001 Feb; 32(3):402-12. PubMed ID: 11170948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telavancin.
    Lyseng-Williamson KA; Blick SK
    Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS; Janc JW
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
    Stryjewski ME; Barriere SL; O'Riordan W; Dunbar LM; Hopkins A; Genter FC; Corey GR
    J Antimicrob Chemother; 2012 Jun; 67(6):1496-502. PubMed ID: 22416054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ; Drew RH
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telavancin: a novel lipoglycopeptide antibiotic.
    Charneski L; Patel PN; Sym D
    Ann Pharmacother; 2009 May; 43(5):928-38. PubMed ID: 19401479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.